Edition:
India

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

49.63USD
19 Jan 2018
Change (% chg)

$-0.06 (-0.12%)
Prev Close
$49.69
Open
$49.63
Day's High
$50.43
Day's Low
$49.34
Volume
206,673
Avg. Vol
331,770
52-wk High
$67.10
52-wk Low
$24.55

Select another date:

Sat, Dec 23 2017

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA® (BETRIXABAN)

BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN

BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch

* Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch

BRIEF-Portola Pharmaceuticals appoints John Lawrence as chief medical officer

* Portola Pharmaceuticals appoints industry veteran John H. Lawrence, M.D., as senior vice president of product development and chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Portola announces pricing of public offering of common stock at $55 per share

* Portola announces pricing of public offering of common stock

BRIEF-Portola Pharma announces proposed offering of common stock

* Portola Pharmaceuticals announces proposed offering of common stock

BRIEF-Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018

* Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA

BRIEF-Portola Pharmaceuticals reports Q2 loss per share of $1.22

* Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Portola announces resubmission of BLA for Andexxa

* Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa)

Select another date: